• Blue and green hydrogen are the two types of hydrogen fuel types being examined for primary use – blue is less expensive but has the potential for higher greenhouse gas production, green hydrogen uses renewable energy sources like solar and wind power and creates a cleaner fuel
• Toyota Motor Corp. has manufactured one of the first hydrogen fuel cell-powered vehicles (Mirai), but there are only a handful of refilling stations available in Britain and three in Australia
• Global green ammonia market size is expected to record a CAGR growth rate of 54% from 2020 to 2025.
• When combusted correctly, carbon-free ammonia has the potential to produce little to no emissions in the form of a water vapor
• FuelPositive Corp. is at the forefront of producing carbon-free ammonia for the creation of alternative zero-emission fuel sources

With a commitment to clean energy solutions, FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is getting the message out about the seriousness of global warming by deploying carbon-free ammonia as a step to help reduce carbon emissions. There is currently a growing interest worldwide in generating carbon-free or green ammonia and green hydrogen fuel to help reduce these emissions. Most of the environmental impacts of hydrogen are dependent on how it is manufactured, and most of the hydrogen produced for power is done so by using a methane source. Blue and green hydrogen are the two hydrogen fuel types currently being examined as primary fuel sources. Blue hydrogen is the cheaper low-carbon hydrogen fuel option, but reports have shown that it emits more greenhouse gases than originally thought. Green hydrogen uses renewable energy sources like solar and wind power to create cleaner hydrogen fuel (https://ibn.fm/fa3Bi). While green hydrogen is the cleanest of all the renewables, it has its problems. Hydrogen on its own is extremely difficult to store and transport. Hydrogen production is energy intensive while the end product is very volatile and requires extreme pressure conditions to store and transport. Additionally, hydrogen transportation raises various safety concerns, especially in the absence of an established distribution infrastructure. FuelPositive’s carbon-free ammonia is an ideal substitute because it provides all the benefits of hydrogen fuel but solves the problems that have been associated with it. The company’s solution is dramatically less expensive to manufacture than pure hydrogen by volume. Its carbon free ammonia system requires 30 percent less energy than conventional ammonia production, with zero carbon emissions. Moreover, FuelPositive’s ammonia stores 65 percent more hydrogen than pure hydrogen by volume and is easy and safer to store and transport via an existing infrastructure. In fact, FuelPositive’s carbon-free NH3 provides the most efficient and safest way to produce, store and transport hydrogen, making it the ideal enabler for the hydrogen economy. With the growing concern of greenhouse gas emissions, there is a higher emphasis worldwide on creating sustainable carbon-free ammonia, known as green ammonia. The global green ammonia market size is expected to record a CAGR growth rate of 54% from 2020 to 2025. The fuel source is considered to be 100% renewable (https://ibn.fm/Nti6j). FuelPositive is uniquely positioned to leverage this expanding market’s opportunities, with its proprietary patent-pending first-of-its-kind carbon-free ammonia technology. The company’s carbon-free ammonia will:

• Help eliminate carbon emissions in agriculture
• Replace fossil fuels used in transportation, including large engine vessels
• Provide affordable and convenient hydrogen for fuel cells
• Provide electricity and grid storage
• Fuel the shift to a hydrogen economy
• Produce carbon credits on a substantial level
• Reduce the need for massive ammonia processing facilities, pipelines and long-distance shipping

FuelPositive’s technology can revolutionize hydrogen production, transport and utilization, at a time when the entire world is looking for innovative hydrogen technologies and solutions. Recently, the Energy Department announced a hydrogen “moonshot” program to invest in new technologies. Additionally, car manufacturer Toyota Motor Corporation (NYSE: TM) has even been exploring the possibility of fueling vehicles with hydrogen with the Mirai model. Only available in certain markets, the car is priced around $100,000. There are currently only a handful of refilling stations in Britain and three in Australia, so purchasing it in another country would not make much sense. The argument is that electric cars will become obsolete, and replacing them with another fuel source, such as hydrogen, will become necessary, according to an article titled ‘Hit the Gas’ by Top Gear host and journalist Jeremy Clarkson. When used properly, carbon-free ammonia only produces discernable emissions in the form of water vapor. Some of these emissions are completely inert. With one of the most polluting industries in the world belonging to agriculture, the development of carbon-free ammonia and hydrogen energy sourcing will help to significantly reduce the impact that this industry has on global warming. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes
• The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics
• The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry
• Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder

Since its inception, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has remained committed to identifying and developing clinical-stage compounds for diseases with high unmet medical needs. It seeks to achieve this through accelerated regulatory pathways, and its main program, Psilocybin-For-Neuropsychiatric Disorders (PFN(TM)) program, is a testament to that. With PFN, Tryp focuses on developing psilocybin-based drug therapies for the treatment of specific neuropsychiatric disorders. So far, psilocybin has shown various advantages over mainstream alternatives already in the market. These benefits include natural blood-brain barrier penetration, increased efficacy, enhanced safety and toxicity profiles and reduced risk of abuse and addiction (https://ibn.fm/JUoAz). Given what Tryp has achieved so far, it is easy to see the potential that psychedelics hold in the treatment of psychological ailments along with other medical conditions with high unmet needs. Additionally, it is easy for one to appreciate the strides that have been taken and the role that companies such as Tryp are making to demystify the usage of these substances for medical purposes. Historically, psilocybin has been used in many specific cultures, not just for medicinal purposes but also to reach an altered state of consciousness. There is evidence of the Aztecs consuming mushrooms and even individuals in the Americas using psychedelics in specific ceremonies. In North Africa and Europe, cave paintings that date back to 4000 BC show psilocybin, thus proving the usage of these substances in particular rituals and medicinal purposes (https://ibn.fm/3zyUF). Fast forward to the prohibition era, which saw great strides in psychedelics research and stringent measures from governments and the United Nations that would, ultimately, see a ban on the possession, sale, and manufacture of psychedelics. The late 19th and early 20th centuries saw Arthur Heffter isolate mescaline from the peyote cactus and Albert Hofmann synthesizing LSD, among other huge milestones. However, the late 20th century saw the UN declaring LSD, DMT, and MDMA as controlled substances. In the 21st century, the scientific community has proven the potential of psychedelics to rewire or repair circuits in the brain. In 2020, research conducted by scientists in Spain showed that DMT could stimulate the production of new brain cells. That same year, Santa Cruz decriminalized psychedelic substances, including peyote, ayahuasca, and psilocybin (https://ibn.fm/Nk3ta). Currently, Tryp continues to contribute to the ongoing conversation regarding the use of psychedelics in the field of medicine. Additionally, bringing light to psilocybin usage in chronic pain indications. With its three strategic initiatives- develop, protect and monetize- Tryp remains committed to utilizing FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to not only shorten the approval timelines but also lower the cost of development programs (https://ibn.fm/6I1oK). This is in a bid to bring psychedelic treatments closer to the people. It also seeks to grow an industry that has been dormant for decades for all the wrong reasons. The psychedelic medical market is still in its early days. There is still a lot that needs to be done. However, one thing that remains true is the industry’s vast potential to transform healthcare. It is projected that by 2027, the medicinal psychedelics market will be valued at $6.8 billion, up from $2 billion in 2019. Experts have even noted that it could eventually become a $100 billion market. Tryp Therapeutics is capitalizing on this potential and leading the accompanying transformation. By doing so, Tryp is stamping its position as a leader in the ongoing psychedelic renaissance. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Radio frequency (“RF”) technology designer and developer AmpliTech Group is leveraging this year’s Nasdaq uplisting and Russell Microcap Index placement to increase its market visibility
• AmpliTech builds and markets communications technology products for the satellite communications, space, telecommunications (5G/6G) and military defense markets
• Markets analysts forecast continued growth over the next five years in the RF component sector, with a CAGR of 13 percent in the multi-billion-dollar sector
• AmpliTech reported a 2021 Q2 55% YOY revenue increase
• A recent follow-on order from an existing global defense and aerospace customer evidences AmpliTech’s growth potential as it continues to build revenues and strategically use its financial resources

The ever-present need for solutions that improve the speed and security of Internet-based technologies is exemplified in the rollout and evolution of 5G wireless communication capabilities worldwide. State-of-the-art RF signal component developer AmpliTech Group (NASDAQ: AMPG, AMPGW) has seen industry attention to its IP for satellite and 5G communications networks grow following its Nasdaq uplisting earlier this year and its more recent inclusion on the Russell Microcap Index in conjunction with the yearly reconstitution of the index, which took effect June 25. AmpliTech strengthened its financial standing with over $30M in funding obtained through recapitalization during the winter and spring months and recently celebrated receipt of a follow-on order for its technology from a long-standing customer in the global defense and aerospace sector. The company reported growth in its year-over-year and sequential quarterly revenues and gross profits when it released Q2 financial figures for the period ending June 30. The company also recently reported a Q2 2021 revenue of $1,024,410 signifying a 55% increase from Q2’20 revenue of $660,699. AmpliTech’s gross profits rose 52.5% to $344,623 in Q2’21 compared to $225,988 in Q2’20. Additionally, the company’s 2021 Q2 results showed record bookings and a record $2.45M backlog (defined as contractually obligated purchase orders with a deadline for delivery). “As the economy reopens in the wake of COVID-19, our target industries and customers are returning to more normal business and procurement patterns, creating a growing range of revenue opportunities for our Company,” President and CEO Fawad Maqbool stated (https://ibn.fm/H5zz6). “We are proud that the performance, quality and return on investment of our solutions continues to earn repeat business from global leaders.” AmpliTech is increasing its product development and marketing efforts to meet pent-up demand it has observed building up in the satellite communications, defense and space industries during the course of the COVID-19 pandemic, as well as for needs in other commercial applications. Analysts at market observer Mordor Intelligence recently forecast growth in the RF components market at a compound annual growth rate (“CAGR”) of 13 percent over the course of the next five years (https://ibn.fm/xwH9a), similar to the pre-pandemic outlook of Grand View Research, Inc., which predicted a 14 percent CAGR to 2025 for revenues of $45.05 billion globally (https://ibn.fm/Ks8Dn). “RF engineering is incorporated into almost everything helping to transmit or receiving a radio wave across the complete RF spectrum (3 kHz to 300 GHz) that includes cellular phones, radios, Bluetooth, and Wi-Fi technology. With the advent of the Internet of Things (‘IoT’) and even greater wireless connectivity, there will be increased demand for RF components,” Mordor’s report stated. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG Safe Harbor Statement This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s ability to execute its business plan as anticipated; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

• The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma
• InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants
• In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries

Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is leading the way as a clinical-stage company developing treatment alternatives using rare pharmaceutical-grade cannabinoids. The company’s operations and programs, in particular its ocular program, were the focus of a presentation given by InMed’s President and CEO Eric A. Adams and Senior Vice President of Pre-Clinical Research and Development Dr. Eric Hsu at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021 (https://ibn.fm/60sc6). In the presentation, Adams and Dr. Hsu gave an overview of InMed’s ocular program, consisting of INM-088, a topical eye drop under development for the treatment of glaucoma using cannabinol (“CBN”). This cannabinoid is showing promise for potential neuroprotection and the reduction of intraocular pressure within the eye. There are over 100 rare cannabinoids that are found in only trace amounts in cannabis. Together, these rare cannabinoids only make up about 1% of the plant’s total biomass – but they are not without their benefits. InMed is currently focused on one cannabinoid, CBN, to meet the unmet needs for medicinal therapeutics for various conditions. The preclinical studies on CBN have shown a promising safety profile and potential therapeutic benefits that exceed tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). In addition to INM-088, InMed is currently developing INM-755, a CBN topical cream geared toward treating epidermolysis bullosa, a genetic skin disorder. INM-755 has been evaluated in two Phase I clinical trials of healthy volunteers to date. The Company has also filed Clinical Trial Applications in several countries as a part of Phase II clinical trials for the same indication. With the availability of rare cannabinoids in the cannabis plant, it is economically impractical for InMed to try and rely solely on the plant as a primary source of these cannabinoids. The Company is developing IntegraSyn, a cannabinoid synthesis manufacturing system, to create these rare cannabinoids in a laboratory setting. The cannabinoids developed in the laboratory setting are bioidentical to the compounds extracted from the natural source. InMed is also focused on the development of proprietary manufacturing technology to produce rare cannabinoids in the lab and already has a on file to acquire a leading cannabinoid manufacturer. In late June, InMed entered a non-binding Letter of Intent (“LOI”) to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacturing and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotech company producing high-quality, regulatory compliant rare cannabinoids, including cannabichromene (“CBC”), and providing them as a B2B supplier to distributors and manufacturers. With a focus on rare cannabinoids and their development in a laboratory setting, InMed is strongly positioned for a prominent role on the U.S. cannabinoid market, a sector valued at $2.3 billion in 2019 and anticipated to grow at a CAGR of 20.4%, resulting in a revenue forecast of $16.4 billion in 2027 (https://ibn.fm/37qod). Much of this growth can be attributed to the increasing number of medical practitioners prescribing cannabinoids for health-related issues. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Red White & Bloom Brands Inc. is set to release its Q2 2021 financial results on Monday, August 30, 2021
• The announcement will also be followed by an update on the company’s asset purchases, accompanying notes along with management discussion and analysis
• Q1 2021 saw outstanding performance for the company, with the CEO announcing intentions to finalize its revised asset purchase of the Michigan investee
• The August 30 announcement will give an update to this and more investment decisions for Q2 2021

On July 27, 2021, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) announced its 2021 1st quarter (“Q1”) financial results (https://ibn.fm/5HQS5). Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company, referred to its performance at the time as “Another great quarter for the company.” When making the announcement, Mr. Rogers also noted that the company would be building on the momentum from Q1, given how much traction it had received for its brand. More so, he pointed out that the company’s priority would be working towards finalizing its revised asset purchase of the Michigan investee in a move to grow sales and revenue. On Monday, August 30, 2021, the company is set to announce its Q2 2021 financial results (https://ibn.fm/xrTmy). It will give an update on asset purchases and other managerial decisions made over that period, including the Michigan investee mentioned above. Red White & Bloom Brands Inc. is a pioneer in the cannabis and hemp-derived product lines. It is strategically positioning itself to be among the top three multi-state operators of these products within the American market. Based in Vancouver, the company is committed to expanding its market reach, a move that has seen investments and pending acquisitions in Michigan and Massachusetts, along with additional plans to enter Florida and California at scale. Red White & Bloom Brands Inc. is set to create the first-ever standardized cannabis facility in the United States, thereby ensuring the superior quality of its products. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• UUUU, RadTran to study the recovery of thorium, radium, from existing rare earth carbonate and uranium process streams
• The alliance has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain
• Partnership aims to alleviate major bottleneck in the targeted alpha therapy market

Due to its highly unique licenses, capabilities, and expertise, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is able to supply critical minerals and materials that no other company in the U.S. – or possibly outside of China – is able to do. Energy Fuels’ business revolves around its ability to recover and properly manage uranium and radionuclides in one-of-a-kind ways in the U.S.  Energy Fuels is the leading U.S. uranium producer. The company just began producing rare earths by unlocking the value of a mineral called monazite, because this mineral contains the radioactive elements, uranium and thorium. And, UUUU’s most recent strategic partnership takes the company into an entirely new realm: the world of medicine. Last month Energy Fuels entered into a strategic alliance with RadTran LLC to evaluate the recovery of thorium, as well as possibly radium, from the company’s existing rare earth carbonate and uranium process streams (https://ibn.fm/cT29O). RadTran is a Colorado-based technology development company focused on closing critical gaps in the procurement of medical isotopes for these applications. The two companies will work together to evaluate the potential to use thorium from existing rare earth and uranium process streams for the production of medical isotopes needed for emerging targeted alpha therapy (“TAT”) cancer therapeutics. “At its heart, the Energy Fuels’ Alliance with RadTran is about maximizing the value and human benefit of our existing uranium and rare earth feeds at the White Mesa Mill,” said UUUU president and CEO Mark S. Chalmers. “Energy Fuels has a long track record of ethically and responsibly processing a wide variety of naturally occurring radioactive materials at the White Mesa Mill for the recovery of uranium and, more recently, rare earths. In our view, recovering medical isotopes from these same streams, that would otherwise be lost to direct disposal, is a great way to maximally use all of our feeds. Indeed, we are essentially replicating China’s ‘monazite plan.’ “China purchases monazite from around the globe, recovers the uranium for use in their nuclear industry, recovers the thorium presumably for use in their nuclear and pharmaceutical industries, and recovers the rare earths for processing into advanced materials needed for various clean energy and advanced technologies,” Chalmers continued. “Our White Mesa Mill is a facility unique to the United States that has the potential to do the same thing at world standards.” According to the announcement, this new initiative complements Energy Fuel’s existing uranium and RE carbonate businesses, as it involves investigating the recovery of isotopes in existing process streams at the company’s White Mesa Mill in Utah. The alliance, UUUU officials pointed out, “has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain.” Uranium and thorium are long-lived, naturally occurring radioactive elements that decay into a series of different elements as they lose alpha or beta particles. Certain elements in or derived from the uranium and thorium decay chains emit alpha particles, which are currently being studied by major pharmaceutical companies that are developing therapies to treat cancer on a cellular level while minimizing damage to surrounding healthy tissue. Supplies of these isotopes are limited, however, and existing production methods are costly and unable to scale-up to meet widespread demand as new drugs are developed and approved. This lack of supply is a major obstacle in the research and development of new TAT drugs. Energy Fuels and its White Mesa Mill may offer a possible solution to this medical supply chain dilemma. The only licensed and operating conventional uranium mill in the United States, the Mill recently began production of RE carbonate from natural monazite sands, which contain thorium-232 and radium-226. Normally these would be disposed of in the Mill’s tailings impoundments, but the new agreement is the first step in recovering these elements for use in medical isotope to treat cancer. “The Alliance between Energy Fuels and RadTran is remarkable as it aims to alleviate the major bottleneck in the targeted alpha therapy market,” said RadTran founder and CEO Dr. Saleem Drera. “Upon the successful production of these isotopes at the Mill, this alliance will allow pharmaceutical companies who are developing targeted alpha therapies to progress through clinical trials and deploy therapeutics commercially without the hinderance of isotope supply.” If successful, this alliance could generate significant future cashflow for Energy Fuels in the medical isotope industry, both in human trials over the next several years and once available for widespread cancer treatment. In addition, the company could play a crucial role in supporting cancer research and creating a new, U.S.-based medical supply chain that adheres to the highest global standards for human rights, sustainability, safety and environmental protection. “We believe Energy Fuels has the potential to create a domestic supply of thorium and possibly radium that can be harvested using RadTran’s technologies for use in the production of the next generation of cancer therapies, a potentially multibillion dollar industry,” said Chalmers. “And we would be accomplishing this in a way that is environmentally beneficial and highly congruent with Energy Fuels’ recycling and sustainability goals. We look forward to working with RadTran on this important initiative.” For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

Date: September 9-10, 2021 Online Livestream Professionals and executives in pharmaceutical, biotech, and medical device companies are invited to attend DGE’s 2nd Human Factors Engineering & Usability Studies Congress being held on September 9-10, 2021. The leading industry conference will offer an educational experience on designing and testing safe and intuitive medical products for all user groups while adapting to regulatory compliance and the unpredictable post-COVID pandemic impact. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking need of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The 2-day event will witness speeches, keynotes, and discussions from leading pharma industry professionals and clinicians. The agenda of the conference:

• FDA feedback on best practices regarding training decay for complex systems and long-travel users
• Detailed analysis on regulatory compliance with remote usability testing for virtual user platforms– both domestic and international
• Novel strategies on analyzing the human needs of wearables and home-use devices
• Ways to bridge the gaps between traditional risk analysis and FDA expectations
• A detailed study to convince management of the importance of increasing spending on human factors issues
• Tracking the impact of machine learning and artificial intelligence on medical device development and testing
• Understand and build effective digital and cloud-based systems around large system design
• Discussions on improving risk-based clinical simulation techniques while keeping the costs under control
• This is the only industry conference featuring a proven interactive streaming platform for human factor engineering and usability study

This is a crucial venue for medical device and combination product professionals to get direct feedback from FDA, and also to find solutions to usability issues while avoiding medication errors and improving the patient experience. Interactive Q&As will give project managers detailed knowledge on how to merge perspectives from diverse teams in order to meet design goals. If you are a vendor looking to offer solutions to these issues, the attendees would like to know what you have to offer – please contact Amy Chapman (achapman@dgeconfs.com or 561-571-7687) to discuss the available options for highlighting your expertise to our audience. Don’t miss this uniquely in-depth event sharing new trends and techniques in human factors and usability! For more details about the event, please visit https://ibn.fm/2ppy9.

• The SaaS sector is projected to grow by $99.99 billion between 2021 and 2025
• It is also projected that in the next few years, SaaS tools will exceed 50,000 globally
• Infobird is positioning itself to capitalize on this growth through innovation and its line of AI-powered solutions
• Its launch and successful implementation of the Intelligent Quality Inspection SaaS in July 2021 marks the company’s commitment to innovation and solving customer needs
• Infobird also continues to set itself apart by involving its customers in the development of Intelligent Quality Inspection SaaS

Experts project that within the next few years, Software-as-a-Service (“SaaS”) tools will exceed 50,000 globally (https://ibn.fm/mvxSt). They note that most mid-market enterprises will use dozens of tools for various functions, with smaller companies using even more to cover every function. They acknowledge and confirm the growing popularity of SaaS along with the unique value proposition it offers to businesses around the world. This sector is projected to grow by $99.99 billion between 2021 and 2025, and Infobird (NASDAQ: IFBD) is positioning itself to make the most out of this growth (https://ibn.fm/L1DPg). Infobird is a SaaS company with a focus on the Chinese market, specifically for the finance segment. It offers Artificial intelligence (“AI”)-enabled end-to-end customer engagement solutions for businesses within this market. The company is constantly innovating and redefining itself. So far, it has 70 Intellectual Property (“IP”) rights developed under its cloud-native architecture and AI technologies. This is aiding with the company’s growth and the expansion of its customer base and market reach. In July 2021, Infobird announced the successful implementation of its Intelligent Quality Inspection SaaS with one of the largest fintech companies in China (https://ibn.fm/DGIyL). This Intelligent Quality Inspection SaaS was explicitly designed to initiate intelligent management and operations for clients’ customer service platforms. Additionally, it lays the foundation for further upgrades of the clients’ customer service, a massive milestone for Infobird. With innovations and new product additions such as these, Infobird is slowly but surely, asserting its position as a leader in the Chinese, global SaaS markets. It is also positioning itself to capitalize on the imminent growth of this sector while making the most out of the various available opportunities. One thing that sets Infobird apart from its competitors is its client involvement when developing Intelligent Quality Inspection SaaS. The company is committed to tailoring the service to the clients’ needs. This often means involving them in the entire process, understanding how they work and function, and their objectives for the software and their business. Infobird goes out of its way to research and analyze its clients’ customer service business scenarios, thereby building a flexible multi-dimensional quality inspection model that is guaranteed to work and guaranteed to be of value to the client (https://ibn.fm/jyv0c). The company also understands that offering a great SaaS experience is more than simply creating the system and getting it to work. Instead, it takes it a step further by conducting customer service training and management work, a move aimed at achieving greater productivity, efficiency, and success. Infobird is an enterprise that understands the potential of the SaaS market, hence its commitment to innovation and solving customer needs and requirements. With its research and development, the company is asserting itself as the industry leader while pushing the next frontier in SaaS, AI, and a fusion of the two. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Plant-based dairy and meat alternatives sales are projected to reach $162 billion in 2030
• The growth will be fueled by the growing popularity of the products and consumers becoming more conscious of the environmental footprint of food
• PlantX intends to capitalize on this growth. So far, it has invested in its infrastructure while also growing its product line that already comprises over 5,000 products

According to a Bloomberg Intelligence report, in 2020, plant-based dairy and meat alternatives totaled $29.4 billion. It is projected that by 2030, sales will have increased to $162 billion, making up 7.7% of the global protein market (https://ibn.fm/RO0Vd). Legacy food companies such as Nestle SA, Tyson Foods Inc., and Kellogg Co. have all noticed this trend and the industry’s potential. Consequently, they have introduced their plant-based meat alternatives and milks to compete with dedicated plant-based food companies such as Beyond Meat Inc., Oatly Inc., and Impossible Foods Inc.Their biggest strength is their overall scale, which they are leveraging to drive distribution, promotion, and marketing. PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is a company that is committed to redefining the plant-based community through e-commerce and going against legacy food companies. Its primary objective is to become the most trusted and convenient destination for anyone interested in living plant-based lives. With its multifaceted marketplace, PlantX’s consumers can not only access a wide range of plant-based products but also enjoy an unrivaled e-commerce experience. They can also be part of a community of individuals living a plant-based lifestyle and enjoy a home delivery system for products, recipes, meals, and more. PlantX acknowledges the potential of the plant-based market, hence its investment in its products and infrastructure. The company also understands the benefits of plant-based products from a health and sustainability standpoint. Meat and dairy substitutes are often marketed as healthier and more sustainable compared to products gotten from animals. As time progresses, consumers are becoming more conscious of the environmental footprint of food (https://ibn.fm/eHvMZ). They are also growing more committed to living healthier lifestyles while having as little impact on the environment as possible. PlantX knows this and has positioned itself to capitalize on this growing trend while leveraging it to have a longer-lasting impact on the market. This is evidenced by its growing product line, which currently comprises over 5,000 products, coupled with its plans to continue to expand its verticals. With the industry projected to grow fivefold by 2030, PlantX seeks to be at the center of this growth. So far, everything seems to be on track. For more information, visit the company’s websites at www.PlantX.com. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols
• AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream
• AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness
• The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of its U.S. operations.

The US and China based cancer screening technology innovator AnPac Bio-Medical Science (NASDAQ: ANPC) is advancing its operations in the United States, announcing Aug. 17 that accomplished bio-medical scientist Dr. Sunil Pandit has been named the CEO of the company’s U.S. operations, AnPac Technology USA Co., Ltd. (or AnPac Bio US). Dr. Pandit will lead the company’s strategic efforts to increase adoption of AnPac Bio’s early cancer detection technology — the pioneering Cancer Differentiation Analysis (“CDA”) platform that is the company’s core product and a proven revenue generator. “AnPac Bio has been recognized for its innovation and leadership in the field of early cancer screening and detection,” Pandit stated in the news release announcing his appointment (https://ibn.fm/KSjtr). “I am confident that given AnPac Bio’s strong innovation and superiority of its novel cancer screening products, we will win customers and market share and become a top tier cancer screening and early detection company in the U.S. in the future.” Blood sample-based cancer screenings generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (ct-DNA), circulating in the blood stream to determine if a cancer exists and is spreading. The novelty of AnPac Bio’s early detection technology is looking for signals to help it assess the risk of cancer occurring before a tumor has developed. In addition to CDA technology’s ability to detect early cancer risk, this technology also has unique advantages in detecting multiple cancer types and is highly cost effective. “Recent studies have shown that there is a correlation between certain biophysical properties, including acoustical, electrical, magnetic, nano-mechanical and optical properties, and cancer occurrence. These studies have revealed that biophysical properties could be important non-genetic aspects of the micro-environment regulating the balance between normal cell growth and carcinogenesis (cancerous growth), which may lead to cancer occurrence,” the company’s Prospectus Supplement filed with the U.S. Securities and Exchange Commission last month states (https://ibn.fm/GfDKx). “Our proprietary CDA device uses an integrated sensor system to detect certain biophysical signals in blood samples,” the supplement adds. “After collecting data on these signals, we use our CDA technology and proprietary algorithm to measure and analyze these signals at multiple biological levels (including the protein, cellular and molecular levels) and with multiple parameters (including the overall CDA value, the PTF value and the CTF value).” PTF and CTF values refer to the Protein Tumor Factor and Cellular Tumor Factor data sets and is proprietary to Anpac Bio CDA technology. Patent applications for the apparatus and methods behind the CDA detection technology began about a decade ago and in 2015 the company performed its first commercial CDA-based test, with the capacity to screen for 16 different types of cancers using a multi-level, multi-parameter approach, well before its current competitors. The company now is able to detect the risk of 26 different cancer types with high sensitivity and specificity. In 2020, despite the global pandemic, the Company’s overall revenue increased by 89.1%, to $3.2 million. The company also pre-announced recently that its test volume in the first half of 2021 has increased 110% over the same period in 2020. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC